Tectonic Therapeutic
Marc brings 15+ years of experience in Biopharma, Consulting, Finance, and Science to Tectonic. Previously, Marc was SVP Business Development and US Operations at Fusion Pharma where his transactional experience included the company’s Series B and IPO. Prior to Fusion, Marc was Head of US Pharma Business Development at Bayer, and held roles in Business Development and Alliance Management at Eisai, Strategy Consulting at Leerink Swann (now Guidehouse), and Healthcare Investment Banking at RBS. Marc has led deals across various therapeutic areas; from early technologies to development-stage and to commercialized assets; buy-side, sell-side, partnerships, and financings; and a mix of deal/financing structures. He holds a PhD in Biochemistry and Molecular Pharmacology from Harvard.
This person is not in any offices
Tectonic Therapeutic
5 followers
Tectonic, co-founded by Andrew Kruse and Tim Springer of Harvard Medical School, is transforming the discovery of antibodies and other biologic drugs targeting G-protein Coupled Receptors (GPCRs).